APR 14, 2021 8:00 AM PDT

AI-Powered Imaging System Can Tell If a Patient Is Cancer-Free

WRITTEN BY: Tara Fernandes

A patient undergoes chemotherapy and radiation for rectal cancer. How do doctors know whether all the malignant tissue has been destroyed?

Washington University in St. Louis researchers have developed a way to answer this question, using an innovative combination of photoacoustic microscopy, ultrasound, and “deep learning” artificial intelligence neural networks.

This new system, called PAM/US, allows physicians to detect the presence of residual tumors within rectal tissue, even differentiating cancer cells from other tissue abnormalities such as scars.

“Our PAM/US system paired with the deep learning neural network has great potential to better identify patients suitable for nonoperative management and improve patient quality of life,” explained Quing Zhu, lead author of the study. 

“If we can tell after radiation and chemotherapy which patients may have a good response with no residual tumors, the patient may be able to avoid surgery.” This is a huge leap forward in the standard of care for patients with non-metastatic rectal cancers, many of which need to undergo invasive follow-up procedures after cancer therapies.

In the study, Zhu and colleagues describe how the technique would be used in a clinical setting. A patient under anesthesia would have a handheld probe inserted into the rectum. There, a rotating head takes a series of images, 360-degrees around the internal rectal wall. The combination of ultrasound and photoacoustic waves transmitted captures intricate details in the underlying vasculature of the rectum and any tumor growth. The whole procedure takes around 20 minutes to complete.

These images are then fed into an AI-based computational system that draws from a library of over 2,000 images captured from rectal cancer patients to make a diagnosis. The algorithm was found to be highly sensitive, correctly predicting the cancer status of 100 percent of rectal cancer patients.

As the next step, the team plans to expand the validation of their new platform by conducting a larger-scale clinical study in rectal cancer patients who have already undergone chemotherapy and radiation.

 

 

Sources: Radiology, Washington University in St. Louis.


 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
OCT 17, 2022
Clinical & Molecular DX
New Study Shows Biological Differences in the Second-Most Common Type of Breast Cancer
OCT 17, 2022
New Study Shows Biological Differences in the Second-Most Common Type of Breast Cancer
Though invasive lobular carcinoma (ILC) is the second-most common type of breast cancer, it has historically been resear ...
OCT 28, 2022
Coronavirus
The New GenElute™-E Viral RNA/DNA Kit
OCT 28, 2022
The New GenElute™-E Viral RNA/DNA Kit
Three Advantages: Reduction in plastic use Time savings Better results Nucleic acids play an essential role in the funct ...
NOV 01, 2022
Cell & Molecular Biology
Understanding the Connection Between Stroke and Shingles
NOV 01, 2022
Understanding the Connection Between Stroke and Shingles
Shingles, or herpes zoster (HZ), is caused by the varicella zoster virus, which is the same virus that causes chicken po ...
NOV 03, 2022
Clinical & Molecular DX
Co-Infections of COVID-19 and the Flu were Common Last Winter, Researchers Find
NOV 03, 2022
Co-Infections of COVID-19 and the Flu were Common Last Winter, Researchers Find
Infections of SARS-CoV-2, or COVID-19, do not always occur on their own. A COVID-19 infection can occur at the same time ...
NOV 18, 2022
Neuroscience
Dopamine and Aversive Events
NOV 18, 2022
Dopamine and Aversive Events
Researchers at the Netherlands Institute for Neuroscience examined how the dopamine system processes aversive, or unplea ...
NOV 22, 2022
Cardiology
The Foods and Behaviors Most Associated with Long-Term Weight Gain
NOV 22, 2022
The Foods and Behaviors Most Associated with Long-Term Weight Gain
Specific dietary and behavioral choices are associated with long-term weight gain.
Loading Comments...